head of rare disease & rare blood disorders , North America
Shannon Resetich leads the North America Rare Disease and Rare Blood Disorders franchises for Sanofi Genzyme. She is responsible for driving the growth of these franchises and enabling the company to reach those patients who may benefit from Sanofi Genzyme’s therapies. Shannon is responsible for all U.S. commercial activities for the Rare Diseases and Rare Blood Disorders franchises inclusive of sales, marketing and patient and provider services. Shannon has an exceptional track record of creating sustainable success and elevating standards of care for patients with rare diseases and specialty conditions. She has more than 20 years of experience leading cross-functional teams in the pharmaceutical, healthcare, and consumer packaged goods sectors.
Shannon joined Sanofi Genzyme in March of 2018 from Activcore, a start-up concierge physical and performance therapy organization where she served as Board Director, EVP & Chief Commercial Officer. Prior to joining Activcore, Shannon was Global Franchise Head, Hematology at Shire, where she was responsible for increasing growth of the $3.6 billion franchise. Prior to Shire’s acquisition of Baxalta, Shannon held positions of increasing responsibility for more than 10 years at Baxter/Baxalta across their Hematology and Pulmonary business. These positions included Region Head, North America Hematology, and U.S. Head, Hematology. Prior to joining Baxter, Shannon spent multiple years in R&D and brand development with Kraft Foods. For the past four years, Shannon has served on the Board of Directors of the Healthcare Businesswomen’s Association (HBA) and she is currently the Chair of the Board. She is a former member of the Board of Directors for the Illinois Biotechnology Innovation Organization (iBIO). Shannon received her MBA from the Kellogg School of Management at Northwestern University and her undergraduate degree in biological engineering from Purdue University.